WJCO
World Journal of Clinical Oncology
Submit a Manuscript: https://www.f6publishing.com
World J Clin Oncol 2025 June 24; 16(6): 106511
DOI: 10.5306/wjco.v16.i6.106511
ISSN 2218-4333 (online)
MINIREVIEWS
Changing paradigms in evaluating adrenal incidentalomas: Bayesian evaluation of [18F]Fluorodeoxyglucose positron emission tomography use, honed on adrenocortical carcinoma
Ioannis Ilias, Georgios Meristoudis
Specialty type: Oncology
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review report’s classification Scientific Quality: Grade C
Novelty: Grade B
Creativity or Innovation: Grade C Scientific Significance: Grade B
P-Reviewer: Tu R
Received: February 28, 2025
Revised: March 20, 2025 Accepted: April 25, 2025
Published online: June 24, 2025 Processing time: 112 Days and 22.2 Hours
Ioannis Ilias, Department of Endocrinology, Hippocration General Hospital, Athens GR-11527, Greece
Georgios Meristoudis, Department of Nuclear Medicine, Hippokration General Hospital, Thessaloniki 54643, Greece
Corresponding author: Ioannis Ilias, MD, PHD, Director, Department of Endocrinology, Hippocration General Hospital, 63, Evrou Street, Athens GR-11527, Greece. iiliasmd@yahoo.com
Abstract
We present the diagnostic performance of [18F]Fluorodeoxyglucose positron emission tomography (FDG PET) for adrenal incidentalomas based on lesion size and unenhanced computed tomography (CT) density in Hounsfield units (HU), following current literature and guidelines. A 20 HU cutoff can be applied to differentiate potentially benign from malignant lesions, particularly in ruling in or out adrenocortical carcinoma. While FDG PET provides valuable metabolic in- formation, its likelihood ratios for a positive (LR+) or negative (LR-) result do not exceed the robust diagnostic thresholds of > 10.0 or < 0.1, respectively. This suggests that positron emission tomography alone is insufficient for definitive characterization and should be integrated with CT or magnetic resonance imaging to leverage their complementary anatomical and functional imaging strengths for optimal diagnostic accuracy.
Key Words: Adrenal gland neoplasms; Diagnosis; Epidemiology; Positron emission tomography; Bayes theorem
@The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
IS Baishideng®
WJCO
Core Tip: [18F]Fluorodeoxyglucose positron emission tomography (FDG PET) diagnostic performance for adrenal incidentalomas (AdIn) was evaluated based on their size as measured on computed tomography (CT) and their unenhanced density in Hounsfield units (HU), using a 20 HU cutoff to assess adrenocortical carcinoma (ACC) risk. The likelihood ratios for positive/negative tests do not meet the usual thresholds, respectively, indicating strong but not definitive diagnostic accuracy. FDG PET should be combined with CT or magnetic resonance imaging for optimal assessment of AdIns.
Citation: Ilias I, Meristoudis G. Changing paradigms in evaluating adrenal incidentalomas: Bayesian evaluation of [18F]Fluorodeoxy- glucose positron emission tomography use, honed on adrenocortical carcinoma. World J Clin Oncol 2025; 16(6): 106511 URL: https://www.wjgnet.com/2218-4333/full/v16/i6/106511.htm DOI: https://dx.doi.org/10.5306/wjco.v16.i6.106511
INTRODUCTION
Adrenal incidentalomas (AdIns) are adrenal masses measuring ≥ 1 cm in diameter, discovered incidentally during imaging studies conducted for non-adrenal indications. The prevalence of AdIns ranges from 3% to 10% in cross-sectional imaging studies, with detection rates increasing with age[1,2].
While the majority of these incidentalomas are benign, non-secreting adenomas, distinguishing them from malignant lesions, particularly adrenocortical carcinoma (ACC), is crucial due to ACC’s aggressive nature and poor prognosis.
ANATOMICAL IMAGING EVALUATION
Computed tomography (CT) remains the cornerstone of AdIns evaluation. On unenhanced CT, adenomas are typically lipid-rich and demonstrate low attenuation values [Hounsfield units (HU) ≤ 10]. This threshold has a specificity of approximately 98% for benign adenomas[3]; however, lipid-poor adenomas may remain indeterminate. For inde- terminate lesions, contrast-enhanced CT with washout analysis can provide additional diagnostic information. Benign adenomas exhibit rapid contrast washout, with an absolute percentage washout > 60% or a relative washout > 40% being highly suggestive of a benign lesion. Size is another important consideration; lesions > 4 cm, especially those with irregular borders, necrosis, or calcifications, are more likely to be malignant and warrant further evaluation. A seminal relevant article from the Cleveland Clinic appeared in 2022: In this work, 2219 patients with AdIn were either followed at least for a year or underwent surgery[4]. This impressive series changed the paradigm of dealing with AdIns, since its authors concluded that the optimal cutoff in adrenal lesion density, which was associated with a higher probability of ACC, is at 20 HU, in lieu of - the until now - accepted value of 10 HU in unenhanced CT. Additionally, the authors found that the increasing probability of ACC vis-à-vis larger AdIn size is lower than previously thought[5]. The cutoff of 20 HU has been integrated in the most recent European Society of Endocrinology AdIns guidelines[6].
Thus, the 20 HU threshold on unenhanced CT is the currently recognized criterion for distinguishing benign lipid-rich adenomas from other adrenal lesions, including lipid-poor adenomas, metastases, and primary adrenal malignancies; nevertheless, the 10 HU threshold is also applied, defining a “grey” zone between 10-20 HU[6]. Additionally, its clinical applicability is influenced by variations in patient demographics, imaging technology, and scanning protocols, ne- cessitating a nuanced approach to its interpretation. The diagnostic performance of the 20 HU threshold is contingent on the prevalence of different adrenal lesion types within specific populations and is specific for lipid-rich adenomas[3]. However, among oncological patients, where adrenal metastases are more common, specificity declines[7]. Notably, in malignancies such as lung cancer or melanoma, up to 30% of adrenal metastases may exhibit HU values below 20, leading to false-negative results[8,9]. Additionally, ethnic and geographic variations may affect the lipid content of adenomas, with studies suggesting higher HU values in certain populations due to genetic or environmental factors[10,11]. Rare adrenal tumors further complicate assessment; for example, myelolipomas, though benign, can contain regions exceeding 20 HU, while atypical pheochromocytomas may present with low attenuation, leading to diagnostic uncertainty. Technical differences across CT scanners and manufacturers can introduce variability in HU measurements. Variations in reconstruction algorithms, slice thickness, and iterative reconstruction techniques may alter HU values, leading to discrepancies in lesion characterization[12,13]. Partial volume averaging in thicker slices (> 5 mm) can artificially lower HU values in small lesions, while beam-hardening artifacts from metallic implants or increased scatter in obese patients further contribute to inconsistencies. The advent of dual-energy CT, offering improved lipid quantification, has the potential to refine the use of the 20 HU threshold by providing more accurate tissue characterization[14,15]. Differences in CT scanning protocols significantly affect the reliability of the 20 HU threshold. Importantly, this threshold is validated only for non-contrast CT; in contrast-enhanced phases, adrenal adenomas may demonstrate attenuation values well above 20 HU, necessitating additional imaging techniques such as delayed contrast washout studies[13]. On venous- phase imaging, adenomas can reach 40-60 HU. Emerging techniques such as spectral CT and virtual non-contrast imaging can help improve lesion differentiation without requiring traditional HU-based cutoffs[15].
Given these limitations, clinicians should incorporate additional imaging modalities when interpreting adrenal lesions. Lesions with HU < 10 are almost always benign lipid-rich adenomas and typically require no further workup unless malignancy risk factors are present. Lesions between 10-20 HU fall within an indeterminate zone where lipid-poor
IS Baishideng®
WJCO
adenomas and malignancies overlap, warranting further characterization. While the 20 HU threshold remains a useful initial tool in adrenal lesion evaluation, its limitations necessitate a more comprehensive approach that integrates patient demographics, imaging technology, and additional imaging modalities. Future advancements in dual-energy CT and artificial intelligence-driven texture analysis hold promise for improving lesion characterization beyond traditional HU thresholds, potentially leading to more precise and individualized diagnostic strategies.
Magnetic resonance imaging (MRI) is another valuable tool, particularly chemical shift MRI, which is useful for differ- entiating lipid-rich adenomas from malignant lesions. A significant signal drop on out-of-phase imaging is characteristic of adenomas due to intracellular lipid content. However, lipid-poor adenomas remain indistinguishable from mali- gnancies using MRI alone, and its superiority over contrast-enhanced CT remains uncertain.
FUNCTIONAL IMAGING: FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN ADRENAL LESION CHARACTERIZATION
[18F]Fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) has emerged as a critical tool in differentiating ACC from benign adrenal lesions due to its ability to assess metabolic activity. ACC typically exhibits intense fluorodeoxyglucose (FDG) uptake due to its high metabolic activity, with standardized uptake values (SUVmax) often exceeding 5. A commonly used semiquantitative parameter is the adrenal-to-liver SUV ratio, with a threshold of > 1.80 strongly suggesting malignancy[16] (other thresholds, ranging from 1.45 to 3.10 have been suggested by various research groups[16,17]). The sensitivity and specificity for FDG-PET/CT in identifying ACC have been reported at approximately 97% and 91%, respectively[18]. In the most recent European Society of Endocrinology AdIns guidelines[6] experts presented updated meta-analyses for the diagnostic characteristics of unenhanced CT and FDG PET (which is usually combined with CT) in evaluating AdIns and ruling in or out the presence of ACC. However, FDG-PET is not without limitations. False-positive findings can occur in pheochromocytomas and metabolically active adenomas, which may demonstrate increased FDG uptake, leading to potential diagnostic pitfalls. Conversely, false-negative results may arise in large necrotic ACCs or lesions with hemorrhagic degeneration, which may exhibit reduced or heterogeneous FDG uptake. While FDG-PET is the preferred functional imaging tool for malignancy detection, other radiotracers, such as 18F- F-DOPA and 68Ga-DOTATATE, may be considered in specific scenarios, such as for pheochromocytomas and paragan- gliomas. Of note, the guidelines on AdIns of the Canadian Urological Association (endorsed by the American Urological Association) leave out assessment with nuclear medicine methods[19], whereas the analogous guidelines of the French Association of Urology suggest the use of CT, MRI and functional/nuclear medicine imaging, primarily with FDG PET [20].
DIAGNOSTIC PERFORMANCE OF FDG-PET ACCORDING TO CT CHARACTERISTICS
In light of the above we believe that the time has come to re-evaluate FDG PET with Bayesian terms in the diagnostic workup of AdIns, as we have already done regarding ACC, AdIns and pheochromocytomas[21,22].
The Bayesian approach can be a valuable tool in the assessment of FDG-PET scans for AdIns, offering a probabilistic and evidence-based estimation of malignancy risk. This methodology integrates pretest probability with imaging-derived data, thereby refining risk stratification and guiding clinical decision-making.
Bayesian inference vis-à-vis AdIns operates by combining prior knowledge-derived from epidemiological data, clinical risk factors, and imaging characteristics, mainly from CT (or MRI)-with observed data from FDG-PET metrics to determine the posterior probability of malignancy. The pretest probability considers patient history, where known primary malignancy significantly increases the risk of ACC, as well as lesion size, where lesions greater than 4 cm raise suspicion. Additional imaging characteristics, such as the HU measurements on non-contrast CT (> 10 HU or > 20 HU suggesting lipid-poor adenoma or malignancy), further refine the baseline probability. The key FDG-PET parameters contributing to the likelihood ratio include the SUVmax, where higher values are more suggestive of malignancy.
Using Bayes’ theorem, the posterior/posttest probability of malignancy (for a positive test) is determined through the equation: Posttest probability = (likelihood ratio x pretest probability)/ evidence.
The pretest probability represents the initial belief about the hypothesis before observing the evidence, the likelihood ratio quantifies how well the new evidence supports the hypothesis and the evidence normalizes the result to ensure probabilities sum to 1. Incorporating the pretest probability, sensitivity and specificity the equation is transformed to: Posttest probability = (pretest probability x sensitivity)/[pretest probability x sensitivity + (1 - pretest probability) x (1 - specificity)].
This approach allows for dynamic risk estimation, thereby improving diagnostic accuracy. In Table 1 we present the diagnostic characteristics of FDG PET according to AdIns CT size and unenhanced CT density in HU, per the recent literature; recent meta-analyses indicate lower sensitivity and specificity for FDG PET compared to older publications[6, 21].
The likelihood ratios of positive tests (LR+) or negative tests (LR-) do not pass the thresholds of > 10.0 or < 0.1, respectively[23]. This indicates that FDG PET is very good, but not excellent, and apparently, has to be combined with CT or MRI to make the best of their characteristics. In the worst-case scenario, a subject with an AdIn larger than 6 cm has almost a one-in-five pre-test probability of harboring ACC, which, post-test, more than doubles to almost a one-in-two probability, with a positive FDG PET scan. In an analogous scenario, a subject with an AdIn having a CT density higher than 20 HU has a 6% pre-test probability of harboring ACC, which, post-test, trebles to 18%, with a positive FDG PET
IS Baishideng®
WJCO
Table 1 Diagnostic characteristics of [18F]Fluorodeoxyglucose positron emission tomography according to adrenal incidentaloma size in computed tomography scans size and unenhanced computed tomography density in Hounsfield units
| CT [18F]FDG PET | ||||||
|---|---|---|---|---|---|---|
| Pre-test probability of ACC (%) | Sensitivity (%) | Specificity (%) | LR+ (95%CI) | LR- (95%CI) | Post-test probability of ACC (%) | |
| Incidentaloma diameter | 90 | 73 | 3.33 (3.26-3.40) | 0.14 (0.11-0.16) | Test (+) | Test (-) |
| < 4 cm 0.1 | 0.1 | 0.0 | ||||
| 4-6 cm 2.4 | 8.0 | 0.0 | ||||
| > 6 cm 19.5 | 45.0 | 3.0 | ||||
| Incidentaloma unenhanced density | Test (+) | Test (-) | ||||
| < 10 HU 0.0 | 0.0 | 0.0 | ||||
| 10-20 HU 0.5 | 2.0 | 0.0 | ||||
| > 20 HU 6.3 | 18.0 | 1.0 | ||||
[18F]FDG PET: [18F]Fluorodeoxyglucose positron emission tomography; CT: Computed tomography; HU: Hounsfield units; ACC: Adrenocortical carcinoma; LR+: Likelihood ratio of a positive test; LR -: Likelihood ratio of a negative test.
scan.
CLINICAL IMPLICATIONS
The integration of FDG-PET into the diagnostic algorithm of AdIns is particularly useful in several scenarios. First, it aids in the evaluation of indeterminate lesions on CT or MRI when washout characteristics or lipid content analysis are inconclusive. Second, it is valuable in cases with high clinical suspicion for ACC, such as in patients with large adrenal masses (> 4 cm) and irregular imaging features. Finally, FDG-PET/CT is instrumental in staging and metastatic workup, particularly in ACC, where metastases may be present at the initial diagnosis.
To enhance clinical decision-making, a structured diagnostic algorithm, integrating CT attenuation values with additional imaging modalities when needed, could be followed:
HU < 10 on unenhanced CT → Consistent with lipid-rich adenoma → No further workup unless high clinical suspicion for malignancy.
HU 10-20 on unenhanced CT → Indeterminate → Consider contrast washout assessment, FDG-PET or chemical-shift MRI.
HU > 20 on unenhanced CT → Potentially lipid-poor adenoma or malignant lesion → Proceed with:
Absolute washout < 60% or relative washout < 40% on delayed contrast CT → Possible malignancy → Consider FDG- PET, biopsy, or surgical evaluation.
Absolute washout ≥ 60% or relative washout ≥ 40% → Likely benign → Clinical follow-up.
Oncological patients/ patients with indeterminate washout/MRI findings - FDG-PET.
Persistent diagnostic uncertainty → Multidisciplinary discussion or biopsy for metastases if clinically appropriate.
This structured approach aims to minimize unnecessary interventions while ensuring timely identification of ma- lignant adrenal lesions.
CONCLUSION
While our study is based on a synthesis of existing literature and retrospective analyses, it provides a comprehensive evaluation of the 10 or 20 HU thresholds and FDG-PET positivity/negativity across diverse adrenal findings. By integrating findings from multiple studies, we aim to offer a critical appraisal of current evidence and highlight the need for future prospective research to further refine adrenal lesion characterization. The comprehensive evaluation of AdIns requires a combination of anatomical and functional imaging. While CT and MRI remain the first-line modalities, FDG- PET has demonstrated substantial utility in differentiating ACC from benign adrenal lesions, especially in cases where traditional imaging is inconclusive. Further refinement of PET-based diagnostic thresholds and prospective validation studies will enhance its clinical applicability in adrenal oncology. By integrating pretest probability with imaging-derived data, the Bayesian approach significantly enhances the diagnostic utility of FDG-PET in evaluating AdIns. This refined risk stratification minimizes unnecessary interventions while improving the identification of high-risk lesions. Future research should focus on refining Bayesian models through machine learning algorithms to further enhance individu- alized malignancy prediction, optimizing clinical workflows and patient outcomes. With the growing worldwide number
IS Baishideng®
WJCO
of PET/CT scanners[24], we believe that further experience on AdIns will be gathered, particularly when combining data from different centers.
FOOTNOTES
Author contributions: Ilias I and Meristoudis G conceived, performed the literature search and wrote this paper; Both authors agree to this paper’s submission.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Country of origin: Greece
ORCID number: Ioannis Ilias 0000-0001-5718-7441; Georgios Meristoudis 0000-0002-0382-6962.
S-Editor: Li L L-Editor: A
P-Editor: Zhao YQ
REFERENCES
1 Sherlock M, Scarsbrook A, Abbas A, Fraser S, Limumpornpetch P, Dineen R, Stewart PM. Adrenal Incidentaloma. Endocr Rev 2020; 41: 775- 820 [RCA] [PMID: 32266384 DOI: 10.1210/endrev/bnaa008] [FullText]
2 Bancos I. Adrenal Incidentalomas: Insights Into Prevalence. Ann Intern Med 2022; 175: 1481-1482 [RCA] [PMID: 36095311 DOI: 10.7326/M22-2600] [FullText]
3 Sabet FA, Majdzadeh R, Mostafazadeh Davani B, Heidari K, Soltani A. Likelihood ratio of computed tomography characteristics for diagnosis of malignancy in adrenal incidentaloma: systematic review and meta-analysis. J Diabetes Metab Disord 2015; 15: 12 [RCA] [PMID: 27104171 DOI: 10.1186/s40200-016-0224-z] [FullText] [Full Text(PDF)]
4 Kahramangil B, Kose E, Remer EM, Reynolds JP, Stein R, Rini B, Siperstein A, Berber E. A Modern Assessment of Cancer Risk in Adrenal Incidentalomas: Analysis of 2219 Patients. Ann Surg 2022; 275: e238-e244 [RCA] [PMID: 32541223 DOI: 10.1097/SLA.0000000000004048] [FullText]
5 Berber E. ASO Author Reflections: How Should Adrenal Incidentalomas be Managed in the Current Era? Ann Surg Oncol 2021; 28: 2763- 2764 [RCA] [PMID: 33236250 DOI: 10.1245/s10434-020-09408-3] [FullText]
6 Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2023; 189: G1-G42 [RCA] [PMID: 37318239 DOI: 10.1093/ejendo/lvad066] [FullText]
7 Grazzini G, Pradella S, De Litteris F, Galluzzo A, Anichini M, Treballi F, Bicci E, Miele V. Adrenal Mass Evaluation: Suspicious Radiological Signs of Malignancy. Cancers (Basel) 2025; 17: 849 [RCA] [PMID: 40075696 DOI: 10.3390/cancers17050849] [FullText]
8 Kim SJ, Lee SW, Pak K, Kim IJ, Kim K. Diagnostic accuracy of (18)F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol 2018; 91: 20170520 [RCA] [PMID: 29327944 DOI: 10.1259/bjr.20170520] [FullText]
9 Park SS, Kim JH. Recent Updates on the Management of Adrenal Incidentalomas. Endocrinol Metab (Seoul) 2023; 38: 373-380 [RCA] [PMID: 37583083 DOI: 10.3803/EnM.2023.1779] [FullText]
10 Kawata S, Obata Y, Akai-Samoto A, Mukai K, Miyashita K, Shimomura I. Atypical Imaging Findings in a Cortisol-producing Adrenal Adenoma Predominantly Composed of Lipid-poor Compact Cells. JCEM Case Rep 2024; 2: luae 189 [RCA] [PMID: 39430734 DOI: 10.1210/jcemcr/luae189] [FullText]
11 Nanba K, Omata K, Gomez-Sanchez CE, Stratakis CA, Demidowich AP, Suzuki M, Thompson LDR, Cohen DL, Luther JM, Gellert L, Vaidya A, Barletta JA, Else T, Giordano TJ, Tomlins SA, Rainey WE. Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. Hypertension 2019; 73: 885-892 [RCA] [PMID: 30739536 DOI: 10.1161/HYPERTENSIONAHA.118.12070] [FullText]
12 Han Z, Wu M, Wei P, Zhu H, Zhang X, Ding Z, Zhang M. Differential diagnostic value of plain CT scan in adrenal adenoma and non- adenoma: A two-center control study of mean attenuation value, minimum attenuation value, and CT histogram. Front Endocrinol (Lausanne) 2022; 13: 1007870 [RCA] [PMID: 36440234 DOI: 10.3389/fendo.2022.1007870] [FullText] [Full Text(PDF)]
13 Bracci B, De Santis D, Del Gaudio A, Faugno MC, Romano A, Tarallo M, Zerunian M, Guido G, Polici M, Polidori T, Pucciarelli F, Matarazzo I, Laghi A, Caruso D. Adrenal Lesions: A Review of Imaging. Diagnostics (Basel) 2022; 12: 2171 [RCA] [PMID: 36140572 DOI: 10.3390/diagnostics12092171] [FullText] [Full Text(PDF)]
14 Cano Alonso R, Álvarez Vázquez A, Andreu Vázquez C, Thuissard Vasallo IJ, Fernández Alfonso A, Recio Rodríguez M, Martínez de Vega V. Dual-energy CT in the differentiation between adrenal adenomas and metastases: Usefulness of material density maps and monochromatic images. Radiologia (Engl Ed) 2023; 65: 402-413 [RCA] [PMID: 37758331 DOI: 10.1016/j.rxeng.2021.10.006] [FullText]
15 Loonis AT, Yu H, Glazer DI, Bay CP, Sodickson AD. Dual Energy-Derived Metrics for Differentiating Adrenal Adenomas From Nonadenomas on Single-Phase Contrast-Enhanced CT. AJR Am J Roentgenol 2023; 220: 693-704 [RCA] [PMID: 36416399 DOI: 10.2214/AJR.22.28323] [FullText]
IS Baishideng®
16 Deandreis D, Leboulleux S, Caramella C, Schlumberger M, Baudin E. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer 2011; 2: 354-362 [PMID: 22076881 DOI: 10.1007/s12672-011-0091-5] [FullText]
17 Groussin L, Bonardel G, Silvéra S, Tissier F, Coste J, Abiven G, Libé R, Bienvenu M, Alberini JL, Salenave S, Bouchard P, Bertherat J, Dousset B, Legmann P, Richard B, Foehrenbach H, Bertagna X, Tenenbaum F. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab 2009; 94: 1713-1722 [RCA] [PMID: 19190108 DOI: 10.1210/jc.2008-2302] [FullText]
18 Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, Blake MA, Hahn PF, Scott JA, Kalra MK. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 2011; 259: 117-126 [RCA] [PMID: 21330566 DOI: 10.1148/radiol.11100569] [FullText]
19 Rowe NE, Kumar R, Schieda N, Siddiqi F, McGregor T, McAlpine K, Violette P, Bathini V, Eng M, Izard J. Diagnosis, Management, and Follow-Up of the Incidentally Discovered Adrenal Mass: CUA Guideline Endorsed by the AUA. J Urol 2023; 210: 590-599 [RCA] [PMID: 37556768 DOI: 10.1097/JU.0000000000003644] [FullText]
20 Savoie PH, Murez T, Rocher L, Neuville P, Escoffier A, Fléchon A, Branger N, Camparo P, Rouprêt M. French AFU Cancer Committee Guidelines - Update 2024-2026 : Assessment of an adrenal incidentaloma and oncological management. Fr J Urol 2024; 34: 102748 [RCA] [PMID: 39581666 DOI: 10.1016/j.fjurol.2024.102748] [FullText]
21 Ilias I, Meristoudis G, Kipouros P, Michalakis K. Caveats in imaging of adrenal masses-incidentalomas: can we diagnose adrenocortical carcinoma by imaging modalities? Hell J Nucl Med 2013; 16: 9-11 [RCA] [PMID: 23570024] [FullText]
22 Ilias I, Meristoudis G, Notopoulos A. A probabilistic assessment of the diagnosis of paraganglioma/pheochromocytoma based on clinical criteria and biochemical/imaging findings. Hell J Nucl Med 2015; 18: 63-65 [RCA] [PMID: 25840574] [FullText]
23 Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen 2003; 10: 47-51 [RCA] [PMID: 12790315 DOI: 10.1258/096914103321610806] [FullText]
24 Gallach M, Mikhail Lette M, Abdel-Wahab M, Giammarile F, Pellet O, Paez D. Addressing Global Inequities in Positron Emission Tomography-Computed Tomography (PET-CT) for Cancer Management: A Statistical Model to Guide Strategic Planning. Med Sci Monit 2020; 26: e926544 [RCA] [PMID: 32848125 DOI: 10.12659/MSM.926544] [FullText] [Full Text(PDF)]
IS Baishideng®
Baishideng®
Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com